LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response | MicrobiomeTrials← Back to trialsNCT07459959
LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-10-01Est. Completion: 2029-06-01
Enrollment target: 40 participants Other microbiome trials you might be interested in
Alzheimer Disease
The purpose of this research study is to evaluate a new radioactive compound used in positron emission tomography (PET) …
St Louis, United StatesCompleted Jan 2027
Aging
Background:
Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other…
Baltimore, United StatesEst. completion Dec 12, 2029
Alzheimer s Disease
Mild Cognitive Impairment
Healthy
Background:
About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disea…
Bethesda, United StatesEst. completion Apr 11, 2029